RESUMO
BACKGROUND AND AIMS: Information on the impact of therapeutic strategies of hepatocellular carcinoma is still incomplete due to the lack of surveys involving primary-care centres. PATIENTS AND METHODS: The Gruppo Epatologico Lombardo (GEL) carried out a study on 361 incident hepatocellular carcinoma observed from January to December 1998 in 22 hospitals in Lombardy. The clinical, pathological and therapeutic data were collected from all patients; 5-year survival and factors related to outcome were analysed. RESULTS: Two hundred and ninety-seven patients were male (M/F: 4.6/1, mean age 66); 61% were HCV-pos, 15% HBV-pos, 17% alcoholic. Cirrhosis was present in 333 (92%) and was classified as Child-A in 197 (59%), Child-B in 85 (26%) and Child-C in 51 (15%) cases. Hepatocellular carcinoma was multifocal/diffuse (more than three nodules) in 91 (25%), less than three nodules in 86 (24%) and monofocal in 184 (51%) (=3cm in 146). As to the therapy: 145 hepatocellular carcinomas (40%) were untreated, 78 (22%) underwent percutaneous ethanol injection/radiofrequency ablation, 75 (20%) transarterial chemoembolization, 32 (9%) liver resection and 3 (0.8%) ortothopic liver transplantation (OLT). Survivals at 1, 3 and 5 years were 75%, 27% and 13%, respectively. Child-Pugh score, small size of the tumour and treatment, regardless of the type, were independent predictors of better prognosis. CONCLUSION: This prospective, region-wide, cohort study showed that the characteristics of hepatocellular carcinoma in Lombardy (1998) do not differ from those reported in previous Italian surveys. Although most hepatocellular carcinomas were discovered at a relatively early stage, a large part remained untreated and the overall prognosis was poor. Efforts are warranted to implement screening-surveillance programmes and the impact of therapeutic strategies.
Assuntos
Carcinoma Hepatocelular/epidemiologia , Carcinoma Hepatocelular/terapia , Neoplasias Hepáticas/epidemiologia , Neoplasias Hepáticas/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Análise de Sobrevida , Resultado do TratamentoRESUMO
This study investigated the Psychosocial adjustment in 40 patients who received orthotopic liver transplantation (OLT) for several endstage liver diseases. Twenty patients were grafted because they suffered from liver Cancer as well as cirrhosis. Particular attention was paid to evaluating whether cancer could affect recipients' coping with transplant. Each patient underwent a semi-structured interview to obtain information on their psychosocial life, relationship with the donor, organ acceptance and life expectancy. Interview was performed I year after transplantation. A psychodiagnostic evaluation was also performed using a Minnesota Multiphasic Personality Inventory (MMPI) and a Human Figure Test. Psychosocial adaptation in everyday life following liver transplantation seemed good in most of the patients, whatever the indication for transplantation might be. It can he seen that by replacing the diseased organ a high percentage of oncological patients overcame their fear of cancer.
Assuntos
Adaptação Psicológica , Neoplasias Hepáticas/psicologia , Transplante de Fígado/psicologia , Adulto , Feminino , Humanos , Relações Interpessoais , Cirrose Hepática/complicações , Cirrose Hepática/psicologia , Cirrose Hepática/cirurgia , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/cirurgia , MMPI , Masculino , Pessoa de Meia-Idade , Técnicas Projetivas , Comportamento Sexual , Doadores de Tecidos/psicologiaRESUMO
A review is made of the literature regarding the present status of ursodeoxycholic acid in the treatment of primary biliary cirrhosis, focusing on the difficulties encountered in establishing the efficacy of this and any other therapy in the management of the disease. It is concluded that further studies or, at least, an updated meta-analysis including the final data emerging from the multicentre, long-term, randomised, double-blind, controlled trials currently under way are needed to establish the clinical importance of ursodeoxycholic acid as a therapeutic agent in primary biliary cirrhosis.